

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Roberts Joseph</u> _____ (Last) (First) (Middle) C/O ARCTURUS THERAPEUTICS HOLDINGS INC. 10285 SCIENCE CENTER DRIVE _____ (Street) SAN DIEGO CA 92121 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 12/12/2025	3. Issuer Name and Ticker or Trading Symbol <u>Arcturus Therapeutics Holdings Inc. [ARCT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <p style="text-align: center;">Controller</p>	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	2,001	D	
Common Stock	200	I	Spouse

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Stock Option (Right to Buy)	(1)	08/24/2028	Common Stock 5,000	8	D	
Stock Option (Right to Buy)	(2)	02/18/2030	Common Stock 5,000	14.12	D	
Stock Option (Right to Buy)	(3)	12/18/2030	Common Stock 2,808	99.29	D	
Stock Option (Right to Buy)	(4)	12/18/2030	Common Stock 6,492	99.29	D	
Stock Option (Right to Buy)	(5)	12/10/2031	Common Stock 7,000	34.57	D	
Stock Option (Right to Buy)	(6)	12/09/2032	Common Stock 7,000	16.92	D	
Stock Option (Right to Buy)	(7)	12/15/2033	Common Stock 7,500	28.88	D	
Stock Option (Right to Buy)	(8)	02/22/2034	Common Stock 1,000	37.44	D	
Stock Option (Right to Buy)	(9)	12/16/2034	Common Stock 9,000	16.24	D	

Explanation of Responses:

- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on August 24, 2018.
- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 18, 2020.
- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 18, 2020.
- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 10, 2021.
- The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 10, 2021.

following three years. The option was granted on December 9, 2022.

7. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 15, 2023.

8. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on February 22, 2024.

9. The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining vesting 1/36th per month over the following three years. The option was granted on December 16, 2024.

/s/ Grant Levine, attorney-
in-fact 12/19/2025

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.